GlycoMark (1,5-AG) Lab: Normal vs Functional Optimal Range Explained

What GlycoMark actually measures

GlycoMark is a commercial serum assay for 1,5-anhydroglucitol (1,5-AG), a dietary polyol that is normally filtered and almost completely reabsorbed by the kidneys. It is not a medication, a hormone, or a peptide. It is a laboratory biomarker in the same general category as HbA1c or fructosamine, used to estimate recent glucose behavior rather than to diagnose disease by itself.

The physiology behind it is well established. Glucose and 1,5-AG compete for reabsorption at the same renal tubular transporter. When blood glucose rises above approximately 180 mg/dL, the kidney spills glucose into the urine, and 1,5-AG is displaced along with it. Serum 1,5-AG then drops within roughly a day or two of a significant glucose excursion and stays low as long as excursions keep happening. This mechanism is the accepted explanation for why 1,5-AG functions as a marker of postprandial hyperglycemia, and it is the basis for the American Diabetes Association's inclusion of 1,5-AG among short-term glycemic markers in its Standards of Care.

GlycoMark reflects a much shorter window than HbA1c, which averages glucose over roughly 90 days with a bias toward the most recent 30 days. GlycoMark's window is closer to 1 to 2 weeks. That shorter window is both the marker's usefulness and its limitation: it can show a change quickly, but a single unusually good or bad week can move the number before any durable change in metabolic health has actually occurred.

A person can have a normal HbA1c and still have frequent after-meal glucose spikes that a 90-day average smooths over. GlycoMark is one of the few blood tests designed to catch that specific pattern without a continuous glucose monitor. Whether a given GlycoMark result should change management, however, depends on how consistently it is confirmed over repeat testing and how it fits with fasting glucose, HbA1c, and CGM data if available. It is not established that 1,5-AG level by itself predicts long-term outcomes such as retinopathy or cardiovascular events in the way HbA1c does; it is a process marker for a physiological pattern, not an outcomes-validated risk score.

Why "normal" on a lab report is not the same as optimal

Laboratories that offer GlycoMark testing report their own reference intervals, generally derived from non-diabetic adult populations and stratified by sex because women tend to run higher baseline 1,5-AG than men. A result that clears the lower limit of that reference range is reported as "normal," even if it sits only marginally above the cutoff.

The interpretive problem is that a marker sitting just inside the normal range can still reflect meaningful postprandial glucose excursions. Some clinical researchers have described a "gray zone" just above the population lower limit where values are statistically normal but functionally consistent with recurring glucose spikes in people without a diabetes diagnosis. This gray-zone concept is a reasonable clinical inference from the renal-threshold mechanism, but the exact numeric boundaries of that zone vary across the published literature and across laboratories, and a specific cutoff should not be quoted to a patient as a settled clinical rule without checking the primary study behind it.

Two things matter for interpretation:

• The reference range is population-derived, not risk-stratified. It tells you whether a value is statistically unusual, not whether it is metabolically optimal.
• Reference ranges must be sex-specific. Applying a male range to a female patient, or vice versa, will misclassify results because baseline dietary intake and renal handling of 1,5-AG differ by sex.

The "functional optimal" range: what it is and how much weight it deserves

Some metabolic and functional medicine clinicians use tighter internal targets for 1,5-AG that sit above the standard laboratory lower limit, on the reasoning that values well above the population floor correlate with fewer excursions above the renal threshold and better time-in-range on continuous glucose monitoring. This is a clinical judgment framework, not an FDA-cleared cutoff or a professional-society-endorsed diagnostic threshold. Readers and clinicians should treat any specific "optimal" number as a starting point for discussion, not as a validated target, until it can be checked against the primary correlation studies that inform it.

GlycoMark, HbA1c, fructosamine, and CGM: which one answers which question

No single glycemic marker covers every use case. The table below compares the tools by the practical decision each one actually helps with, not by keyword.

Read this table as a decision aid, not a hierarchy. If a patient already has good CGM data, GlycoMark adds little. If CGM is not available or affordable, GlycoMark is one of the only blood-based proxies for postprandial behavior, with the caveat that it is a proxy and not a direct measurement.

What distorts a GlycoMark result independent of glucose control

Interpreting a GlycoMark value in isolation, without checking for these confounders, risks both false reassurance and false alarm.

SGLT2 inhibitors. Medications such as empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin work by blocking renal glucose reabsorption at the same transporter system involved in 1,5-AG handling. This causes ongoing urinary 1,5-AG loss regardless of how well glucose is actually controlled, so GlycoMark reads falsely low. This is a well-recognized limitation and GlycoMark should generally not be used, or should be interpreted with major caution, in patients taking these drugs.

Reduced kidney function. Significant chronic kidney disease reduces the kidney's ability to spill glucose into urine in the first place, which can make 1,5-AG appear falsely reassuring even when glucose control is poor. Reference ranges are validated in people with normal renal function, not in advanced CKD.

Diet. 1,5-AG is present in rice, wheat, soy, and other plant foods, so short-term dietary shifts can nudge levels modestly. This effect is small relative to the renal-threshold effect, but it is one reason single data points are less useful than a trend across repeat testing.

Pregnancy. Renal glucose handling changes in pregnancy, and standard non-pregnant reference ranges do not apply. GlycoMark is not a validated tool for gestational diabetes monitoring.

When ordering GlycoMark makes sense, and when it does not

GlycoMark may add information in a few specific situations: when HbA1c is normal or near-normal but a patient reports symptoms suggestive of after-meal glucose spikes, when a clinician wants an early signal after starting a new diet, medication, or GLP-1 receptor agonist before HbA1c would be expected to move, or when fasting glucose looks fine but postprandial variability is suspected.

It generally should not be ordered, or should be interpreted with explicit caveats, in patients currently taking an SGLT2 inhibitor, in patients with significantly reduced kidney function, or during pregnancy. It is also not a substitute for HbA1c in diagnosing diabetes or prediabetes; it is an adjunct marker for a specific physiological question about recent postprandial glucose behavior.

What might raise a low GlycoMark, and what is not established

If a low GlycoMark reflects repeated glucose excursions above the renal threshold, raising it means reducing those excursions. Several interventions plausibly move postprandial glucose in that direction based on general diabetes and obesity evidence, though the exact effect on 1,5-AG specifically, and the timeline for it, has not been directly established in this article's source material and should be confirmed against the primary trials before quoting specific numbers to patients:

• Reducing refined carbohydrate intake lowers postprandial glucose peaks in people with prediabetes and early type 2 diabetes; structured lifestyle and weight-management programs, including the DiRECT primary-care trial, have shown meaningful glycemic improvement with sustained dietary change, though DiRECT measured HbA1c and diabetes remission rather than 1,5-AG directly.
• GLP-1 receptor agonists such as semaglutide and tirzepatide reduce postprandial glucose excursions through delayed gastric emptying and glucose-dependent insulin secretion, and large trials such as STEP-1 have documented substantial weight loss and glycemic improvement with semaglutide 2.4 mg; the specific magnitude of weight loss and glucose change should be checked against the original New England Journal of Medicine publication rather than repeated from memory.
• Short walks after meals have been studied as a way to blunt postprandial glucose in people at risk for impaired glucose tolerance, published in Diabetes Care; the exact percentage reduction reported in that trial should be verified before citing a specific number.
• Metformin mainly reduces fasting hepatic glucose output, with a more modest postprandial effect. Alpha-glucosidase inhibitors specifically blunt post-meal spikes by slowing carbohydrate digestion. Both are reasonable candidates for improving a postprandial marker like 1,5-AG, though head-to-head data on GlycoMark change specifically was not available in the material reviewed for this article.

None of this is dosing guidance. Any medication decision, including starting or adjusting a GLP-1 receptor agonist or an alpha-glucosidase inhibitor, belongs with a treating clinician who can weigh contraindications, kidney function, and other medications.

Evidence boundary: what is established, what is plausible, what is not

Established: the renal-threshold mechanism linking 1,5-AG to postprandial glucose excursions above roughly 180 mg/dL; the roughly 1 to 2 week reflection window, shorter than HbA1c's roughly 90-day average; SGLT2 inhibitors as a major confounder that invalidates the test; recognition of 1,5-AG as a short-term glycemic marker in ADA Standards of Care.

Plausible but not firmly established in the material reviewed here: specific numeric "functional optimal" cutoffs above the standard lab reference range; precise correlations between a given 1,5-AG value and CGM time-in-range percentage; the exact timeline (days versus weeks) for 1,5-AG to rise after a specific dietary or pharmacologic intervention.

Not established: that targeting a 1,5-AG number itself, independent of HbA1c and other markers, changes long-term outcomes such as cardiovascular events or microvascular complications; validated reference ranges in pregnancy or advanced kidney disease; use of GlycoMark as a stand-alone diagnostic test for diabetes or prediabetes.

If a GlycoMark result seems inconsistent with how a patient feels, or if there is any concern about very high glucose (extreme thirst, frequent urination, blurred vision, confusion, or unexplained weight loss), that warrants prompt evaluation rather than waiting for a repeat lab draw.

References

1. American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes. Diabetes Care (current edition). https://diabetesjournals.org
2. Endocrine Society. Clinical Practice Guidelines. https://www.endocrine.org/clinical-practice/guidelines